Table 3 MDACC CRES grading31
From: The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
Symptom/sign | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|
Neurological assessment score (by CARTOX-10) | 7–9 (mild) | 3–6 (moderate) | 0–2 (severe) | Critical condition and/or obtunded and cannot perform assessment of tasks |
Raised intracranial pressure | — | — | Stage 1–2 papilloedemaa, or CSF opening pressure <20 mm Hg limiting self-care ADL | Stage 3–5 papilloedemaa, or CSF opening pressure ≥20 mm Hg, or cerebral edema |
Seizures or motor weakness | — | — | Partial seizure, or non-convulsive seizures on EEG with response to benzodiazepine | Generalized seizures, or convulsive or non-convulsive status epilepticus, or new motor weakness |
